OR WAIT null SECS
CrystecPharma has opened a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility in Haimen City, Jiangsu Province, China.
CrystecPharma, a pharmaceutical crystal and particle engineering company, has opened a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility in Haimen City, Jiangsu Province, China.
According to a March 31, 2021 press release, the R&D center was established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform—an initiative jointly funded by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the Haimen government. The platform is aimed at accelerating pharmaceutical product innovation underpinned by advanced pharmaceutical excipients and drug delivery technologies. Crystec’s proprietary supercritical fluid technology, mSAS, will play a role in enabling the development of new therapeutics, creation of value-added medicines, and in the simplification of formulations and manufacturing processes.
“We are delighted to open our new facility in Haimen, a project credited to the collaborative efforts of SIMM, Chinese Academy of Sciences, and the Haimen government,” said Qun Shao, Crystec’s chief operations officer, in the press release. “This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China.”